Therapeutic failures in epileptic children due to impaired diphenylhydantoin bioavailability

G. Koren, S. Daney, N. Brand, H. Halkin

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

The serum level approach to individualization of diphenylhydantion (DPH) therapy in epilepsy is well established. When universally applied it may help to reveal causes of inappropriate therapeutic responses. We report here a high rate of therapeutic failure with DPH in epileptic children, with widespread low serum DPH concentrations despite adequate doses. Impaired bioavailability of the local oral DPH formulation in use was confirmed by a crossover comparison with a standard imported oral formulation.

Original languageEnglish
Pages (from-to)721-723
Number of pages3
JournalIsrael Journal of Medical Sciences
Volume18
Issue number6
StatePublished - 1982
Externally publishedYes

Fingerprint

Dive into the research topics of 'Therapeutic failures in epileptic children due to impaired diphenylhydantoin bioavailability'. Together they form a unique fingerprint.

Cite this